\-\ Texto\\:\\ \ \(0\)\
\-\ patient\\ had\\ abdominal\\ distension\\ and\\ a\\ mass\\ was\\ palpated\\ in\\ the\\ rlq\\.\\ abdomen\\ was\\ diffusely\\ tender\\ to\\ palpation\\.\\ no\\ rebound\\ or\\ guarding\\ was\\ noted\\.\\ bowel\\ sounds\\ were\\ diminished\\.\ \(0\)\
\-\ after\\ the\\ discovery\\ of\\ many\\ metastases\\ within\\ the\\ abdomen\\ on\\ ct\\,\\ the\\ patient\\ underwent\\ surgery\\ for\\ biopsy\\ and\\ resection\\ of\\ the\\ tumor\\.\\ tissue\\ was\\ removed\\ from\\ the\\ abdominal\\ mass\\ as\\ well\\ as\\ a\\ vaginal\\ nodule\\,\\ a\\ uterine\\ nodule\\,\\ a\\ rectosigmoid\\ nodule\\,\\ a\\ vena\\ cava\\ lymph\\ node\\ and\\ the\\ appendix\\.\\ the\\ abdominal\\ mass\\ tissue\\ was\\ partially\\ encapsulated\\,\\ lobulated\\ and\\ yellow\\-tan\\ in\\ appearance\\ with\\ a\\ size\\ of\\ 20cm\\ x\\ 11cm\\ x\\ 11cm\\.\\ the\\ mass\\ weighed\\ 1355g\\.\\ the\\ tumor\\ was\\ compatible\\ with\\ rhabdomyosarcoma\\ on\\ frozen\\ section\\.\\ the\\ patient\\ had\\ metastatic\\ disease\\ \\(group\\ iv\\)\\ and\\ was\\ subsequently\\ treated\\ with\\ systemic\\ chemotherapy\\ and\\ radiation\\.\\ at\\ 6\\ month\\ follow\\ up\\,\\ the\\ patient\\ had\\ no\\ evidence\\ of\\ new\\ metastasis\\ and\\ was\\ tolerating\\ chemotherapy\\.\ \(0\)\
\-\ x\\-ray\\ demonstrates\\ abdominal\\ distension\\.\ \(0\)\
\-\ ct\\ demonstrates\\ multiple\\ ovarian\\ metastases\\ throughout\\ the\\ abdomen\\,\\ including\\ the\\ liver\\,\\ and\\ large\\ bowel\\.\ \(0\)\
\-\ malignant\\ rhabdomyosarcoma\ \(0\)\
\-\ rhabdomyosarcoma\ \(41\)\
\-\ dysgerminoma\ \(2\)\
\-\ malignant\\ teratoma\ \(0\)\
\-\ embryonal\\ carcinoma\ \(7\)\
\-\ 15\\ y\\/o\\ presents\\ with\\ 2\\ month\\ history\\ of\\ abdominal\\ pain\ \(1\)\
\-\ rhabdomyosarcoma\\ is\\ a\\ frequent\\ cause\\ of\\ death\\ due\\ to\\ malignant\\ disease\\ in\\ children\\ and\\ is\\ the\\ most\\ common\\ soft\\ tissue\\ sarcoma\\ in\\ pediatrics\\.\\ roughly\\ 10\\%\\ of\\ all\\ solid\\ tumors\\ in\\ childhood\\ are\\ rhabdomyosarcomas\\.\\ these\\ tumors\\ are\\ extremely\\ malignant\\ and\\ tend\\ to\\ invade\\ locally\\ and\\ metastases\\ by\\ hematogenous\\ and\\ lymphatic\\ routes\\.\\ without\\ treatment\\,\\ 90\\%\\ of\\ patients\\ die\\ within\\ one\\ year\\ of\\ diagnosis\\.\\ rhabdomyosarcomas\\ are\\ equal\\ between\\ genders\\ and\\ are\\ bimodal\\ in\\ age\\ distribution\\ with\\ peaks\\ at\\ 4\\-6\\ years\\ and\\ 16\\-18\\ years\\ of\\ age\\.\\ these\\ tumors\\ are\\ thought\\ to\\ arise\\ from\\ totipotent\\ mesenchymal\\ cells\\ and\\ the\\ histologic\\ diagnosis\\ can\\ be\\ difficult\\.\\ histologic\\ types\\ that\\ can\\ be\\ seen\\ in\\ a\\ rhadomyosarcoma\\ include\\ alveolar\\,\\ embryonal\\,\\ embryonal\\-botryoid\\,\\ pleomorphic\\,\\ and\\ undifferentiated\\.\\ among\\ these\\ types\\,\\ the\\ alveolar\\ variety\\ has\\ the\\ worst\\ prognosis\\.\\ the\\ botyroides\\ type\\ has\\ the\\ classic\\ grape\\-like\\ appearance\\.\\ rhabdomyosarcomas\\ most\\ commonly\\ originate\\ from\\ the\\ pelvis\\ and\\ gu\\ tract\\ with\\ nearly\\ 40\\%\\ in\\ these\\ areas\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ rhabdomyosarcomas\\:\\ 0\\.2681695455385369\ \(0\)\
\-\ the\\:\\ 0\\.23421876173562106\ \(0\)\
\-\ rhabdomyosarcoma\\:\\ 0\\.22625908204676645\ \(0\)\
\-\ embryonal\\:\\ 0\\.19637325240307657\ \(0\)\
\-\ and\\:\\ 0\\.19635375625422452\ \(0\)\
\-\ 11cm\\:\\ 0\\.1787796970256913\ \(0\)\
\-\ malignant\\:\\ 0\\.15937860005904309\ \(0\)\
\-\ was\\:\\ 0\\.155842433186546\ \(0\)\
\-\ abdominal\\:\\ 0\\.15285498444379328\ \(0\)\
\-\ metastases\\:\\ 0\\.1355663623165407\ \(0\)\
\-\ nodule\\:\\ 0\\.1323562925506288\ \(0\)\
\-\ these\\:\\ 0\\.12625781541116138\ \(0\)\
\-\ histologic\\:\\ 0\\.1250657486677098\ \(0\)\
\-\ tumors\\:\\ 0\\.12332585837642684\ \(0\)\
\-\ alveolar\\:\\ 0\\.11733146476076277\ \(0\)\
\-\ distension\\:\\ 0\\.11609330849137461\ \(0\)\
\-\ in\\:\\ 0\\.1112408559900005\ \(0\)\
\-\ of\\:\\ 0\\.10938596845651823\ \(0\)\
\-\ are\\:\\ 0\\.1060499207551352\ \(0\)\
\-\ types\\:\\ 0\\.10396161171898208\ \(0\)\
\-\ abdomen\\:\\ 0\\.10231759737472237\ \(0\)\
\-\ 1355g\\:\\ 0\\.08938984851284565\ \(0\)\
\-\ genders\\:\\ 0\\.08938984851284565\ \(0\)\
\-\ totipotent\\:\\ 0\\.08938984851284565\ \(0\)\
\-\ rhadomyosarcoma\\:\\ 0\\.08938984851284565\ \(0\)\
\-\ botyroides\\:\\ 0\\.08938984851284565\ \(0\)\
\-\ tissue\\:\\ 0\\.08796532146530413\ \(0\)\
\-\ mass\\:\\ 0\\.08540309636650706\ \(0\)\
\-\ had\\:\\ 0\\.08354830452290511\ \(0\)\
\-\ dysgerminoma\\:\\ 0\\.08259783009220151\ \(0\)\
\-\ routes\\:\\ 0\\.08041128854160368\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.07937969449740176\ \(0\)\
\-\ rectosigmoid\\:\\ 0\\.07862475401191736\ \(0\)\
\-\ 20cm\\:\\ 0\\.07862475401191736\ \(0\)\
\-\ tolerating\\:\\ 0\\.07862475401191736\ \(0\)\
\-\ bimodal\\:\\ 0\\.07580581167155737\ \(0\)\
\-\ weighed\\:\\ 0\\.0746516779316332\ \(0\)\
\-\ die\\:\\ 0\\.0746516779316332\ \(0\)\
\-\ peaks\\:\\ 0\\.07361927012095953\ \(0\)\
\-\ patient\\:\\ 0\\.07272063143814655\ \(0\)\
\-\ frozen\\:\\ 0\\.07183273559127322\ \(0\)\
\-\ bowel\\:\\ 0\\.07174314786895324\ \(0\)\
\-\ invade\\:\\ 0\\.07104841220339228\ \(0\)\
\-\ undifferentiated\\:\\ 0\\.07104841220339228\ \(0\)\
\-\ pediatrics\\:\\ 0\\.07032224216894441\ \(0\)\
\-\ originate\\:\\ 0\\.07032224216894441\ \(0\)\
\-\ age\\:\\ 0\\.070184105417121\ \(0\)\
\-\ years\\:\\ 0\\.06852698163967388\ \(0\)\
\-\ discovery\\:\\ 0\\.06841974402201906\ \(0\)\
\-\ month\\:\\ 0\\.0680043473983227\ \(0\)\
\-\ appearance\\:\\ 0\\.06739504580694147\ \(0\)\
\-\ encapsulated\\:\\ 0\\.0673298650126199\ \(0\)\
\-\ roughly\\:\\ 0\\.0673298650126199\ \(0\)\
\-\ locally\\:\\ 0\\.0668272517003154\ \(0\)\
\-\ from\\:\\ 0\\.06659854642547347\ \(0\)\
\-\ with\\:\\ 0\\.06567079592796345\ \(0\)\
\-\ mesenchymal\\:\\ 0\\.06545775080102552\ \(0\)\
\-\ gu\\:\\ 0\\.06425639378274814\ \(0\)\
\-\ lymphatic\\:\\ 0\\.06388658343070491\ \(0\)\
\-\ worst\\:\\ 0\\.06388658343070491\ \(0\)\
\-\ hematogenous\\:\\ 0\\.06353022374830027\ \(0\)\
\-\ palpated\\:\\ 0\\.06003523327967125\ \(0\)\
\-\ among\\:\\ 0\\.05910130681345822\ \(0\)\
\-\ variety\\:\\ 0\\.05910130681345822\ \(0\)\
\-\ can\\:\\ 0\\.05866488419718007\ \(0\)\
\-\ tumor\\:\\ 0\\.05847368636271607\ \(0\)\
\-\ most\\:\\ 0\\.05817992634835382\ \(0\)\
\-\ rlq\\:\\ 0\\.05804665424568731\ \(0\)\
\-\ diagnosis\\:\\ 0\\.057952164832370784\ \(0\)\
\-\ extremely\\:\\ 0\\.057277725694112186\ \(0\)\
\-\ tend\\:\\ 0\\.05709456501006077\ \(0\)\
\-\ childhood\\:\\ 0\\.05656477051169161\ \(0\)\
\-\ pleomorphic\\:\\ 0\\.05656477051169161\ \(0\)\
\-\ demonstrates\\:\\ 0\\.056163070033750505\ \(0\)\
\-\ compatible\\:\\ 0\\.05590018968876069\ \(0\)\
\-\ to\\:\\ 0\\.0558955457554449\ \(0\)\
\-\ nearly\\:\\ 0\\.05574085591321076\ \(0\)\
\-\ diminished\\:\\ 0\\.05542975640962495\ \(0\)\
\-\ death\\:\\ 0\\.054835707180730775\ \(0\)\
\-\ guarding\\:\\ 0\\.05469265630009723\ \(0\)\
\-\ vena\\:\\ 0\\.05400714529200721\ \(0\)\
\-\ vaginal\\:\\ 0\\.05387561564878925\ \(0\)\
\-\ cava\\:\\ 0\\.053745828171331625\ \(0\)\
\-\ equal\\:\\ 0\\.05349129928181985\ \(0\)\
\-\ rebound\\:\\ 0\\.05324321485902711\ \(0\)\
\-\ group\\:\\ 0\\.05312148892977662\ \(0\)\
\-\ uterine\\:\\ 0\\.052198566183184934\ \(0\)\
\-\ diffusely\\:\\ 0\\.05198080585949104\ \(0\)\
\-\ lobulated\\:\\ 0\\.05155928662073378\ \(0\)\
\-\ within\\:\\ 0\\.05148793406342593\ \(0\)\
\-\ frequent\\:\\ 0\\.05125463582504317\ \(0\)\
\-\ arise\\:\\ 0\\.0511551546528899\ \(0\)\
\-\ has\\:\\ 0\\.05106331449778648\ \(0\)\
\-\ section\\:\\ 0\\.05095917189409527\ \(0\)\
\-\ appendix\\:\\ 0\\.050393698979688865\ \(0\)\
\-\ systemic\\:\\ 0\\.04960233368615589\ \(0\)\
\-\ prognosis\\:\\ 0\\.0491888203760032\ \(0\)\
\-\ teratoma\\:\\ 0\\.04833621231252992\ \(0\)\
\-\ thought\\:\\ 0\\.04826225866871866\ \(0\)\
\-\ node\\:\\ 0\\.048043688760086634\ \(0\)\
\-\ partially\\:\\ 0\\.0479719022756988\ \(0\)\
\-\ subsequently\\:\\ 0\\.04768990263286241\ \(0\)\
\-\ ovarian\\:\\ 0\\.047620652794866616\ \(0\)\
\-\ removed\\:\\ 0\\.04748360424905665\ \(0\)\
\-\ distribution\\:\\ 0\\.04741579213555805\ \(0\)\
\-\ disease\\:\\ 0\\.04692629751653014\ \(0\)\
\-\ sarcoma\\:\\ 0\\.04688955502016246\ \(0\)\
\-\ tract\\:\\ 0\\.046825718890201116\ \(0\)\
\-\ difficult\\:\\ 0\\.04639014445712428\ \(0\)\
\-\ children\\:\\ 0\\.04579967601076331\ \(0\)\
\-\ be\\:\\ 0\\.04534953298190059\ \(0\)\
\-\ as\\:\\ 0\\.04491080184143719\ \(0\)\
\-\ 90\\:\\ 0\\.044664661908696654\ \(0\)\
\-\ many\\:\\ 0\\.04407061267980248\ \(0\)\
\-\ lymph\\:\\ 0\\.04346526798995366\ \(0\)\
\-\ sounds\\:\\ 0\\.04315416848636785\ \(0\)\
\-\ cells\\:\\ 0\\.04306706736803206\ \(0\)\
\-\ solid\\:\\ 0\\.042852642809916956\ \(0\)\
\-\ ct\\:\\ 0\\.04256025252731033\ \(0\)\
\-\ at\\:\\ 0\\.04222524227401018\ \(0\)\
\-\ classic\\:\\ 0\\.041807517526604034\ \(0\)\
\-\ commonly\\:\\ 0\\.041360345885469336\ \(0\)\
\-\ throughout\\:\\ 0\\.04110861945880895\ \(0\)\
\-\ 40\\:\\ 0\\.04110861945880895\ \(0\)\
\-\ metastasis\\:\\ 0\\.04096762693577001\ \(0\)\
\-\ tender\\:\\ 0\\.040863198118324506\ \(0\)\
\-\ including\\:\\ 0\\.040001937682286326\ \(0\)\
\-\ iv\\:\\ 0\\.039938719325631186\ \(0\)\
\-\ biopsy\\:\\ 0\\.039181092406083695\ \(0\)\
\-\ pelvis\\:\\ 0\\.0390939912877479\ \(0\)\
\-\ new\\:\\ 0\\.038669734058577515\ \(0\)\
\-\ liver\\:\\ 0\\.03855963389695958\ \(0\)\
\-\ underwent\\:\\ 0\\.03850504427781467\ \(0\)\
\-\ cause\\:\\ 0\\.03807894187185828\ \(0\)\
\-\ areas\\:\\ 0\\.03794949730393133\ \(0\)\
\-\ size\\:\\ 0\\.03784715891895914\ \(0\)\
\-\ 15\\:\\ 0\\.03777110049342072\ \(0\)\
\-\ palpation\\:\\ 0\\.03769562788955478\ \(0\)\
\-\ type\\:\\ 0\\.03749716416779037\ \(0\)\
\-\ radiation\\:\\ 0\\.03704132331323246\ \(0\)\
\-\ no\\:\\ 0\\.036353476555651514\ \(0\)\
\-\ between\\:\\ 0\\.036318502727216824\ \(0\)\
\-\ resection\\:\\ 0\\.03583005348551779\ \(0\)\
\-\ treated\\:\\ 0\\.03480800930488802\ \(0\)\
\-\ on\\:\\ 0\\.03376309378310673\ \(0\)\
\-\ carcinoma\\:\\ 0\\.03343445176662774\ \(0\)\
\-\ all\\:\\ 0\\.0332735481299824\ \(0\)\
\-\ include\\:\\ 0\\.033257602135750415\ \(0\)\
\-\ 10\\:\\ 0\\.032685133100357824\ \(0\)\
\-\ due\\:\\ 0\\.032130059487566975\ \(0\)\
\-\ one\\:\\ 0\\.03200307527469521\ \(0\)\
\-\ evidence\\:\\ 0\\.03172664477707386\ \(0\)\
\-\ common\\:\\ 0\\.03169942583931338\ \(0\)\
\-\ patients\\:\\ 0\\.031444548479476954\ \(0\)\
\-\ metastatic\\:\\ 0\\.030656151588609445\ \(0\)\
\-\ is\\:\\ 0\\.030614990467905112\ \(0\)\
\-\ follow\\:\\ 0\\.03013278971128997\ \(0\)\
\-\ surgery\\:\\ 0\\.03005204566518079\ \(0\)\
\-\ soft\\:\\ 0\\.029757832924625763\ \(0\)\
\-\ noted\\:\\ 0\\.029635969370654682\ \(0\)\
\-\ without\\:\\ 0\\.02948303052674378\ \(0\)\
\-\ were\\:\\ 0\\.028812765114070778\ \(0\)\
\-\ large\\:\\ 0\\.0280066631240982\ \(0\)\
\-\ up\\:\\ 0\\.027649637512759728\ \(0\)\
\-\ multiple\\:\\ 0\\.027339942755974848\ \(0\)\
\-\ after\\:\\ 0\\.02711605859364522\ \(0\)\
\-\ well\\:\\ 0\\.027065111453087435\ \(0\)\
\-\ presents\\:\\ 0\\.026888853992340873\ \(0\)\
\-\ treatment\\:\\ 0\\.02662622356347294\ \(0\)\
\-\ seen\\:\\ 0\\.026315377131628594\ \(0\)\
\-\ that\\:\\ 0\\.024256761278166034\ \(0\)\
\-\ by\\:\\ 0\\.023736677027733927\ \(0\)\
\-\ history\\:\\ 0\\.021355502106817695\ \(0\)\
\-\ pain\\:\\ 0\\.020001640457734886\ \(0\)\
\-\ or\\:\\ 0\\.019445217855952202\ \(0\)\
\-\ year\\:\\ 0\\.017226042061066774\ \(0\)\
\-\ for\\:\\ 0\\.016941644051984305\ \(0\)\
